AbCellera Biologics Inc. — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbCellera Biologics Inc. (ABCL)
CIK: 0001703057
Period of Report: 2021-06-07

Reporting Person: Booth Andrew (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-07	Common Shares	M	600000	$0.19	Acquired	600000	Direct
2021-06-07	Common Shares	M	600000	$0.32	Acquired	1200000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-07	Share Option (right to buy)	$0.19	M	600000	Disposed	2026-06-15	Common Shares (600000)	Direct
2021-06-07	Share Option (right to buy)	$0.32	M	600000	Disposed	2029-08-22	Common Shares (600000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	116959	Indirect

Footnotes

F1: The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2: 2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.